AzTrials
AzTrials

CholecystectomyPhase 3NCT04622813

Nonopioid Analgesics and Cholecystectomy

A Phase 3 study testing nefopam, ketoprofen, paracetamol and saline infusion, ketoprofen, paracetamol in people with Cholecystectomy and Pain, Postoperative, run by American University of Beirut Medical Center at 1 site in Lebanon.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate the effect of the addition of nefopam to a multimodal analgesic regimen consisting of ketoprofen and paracetamol during sevoflurane- dexmedetomidine-based anesthesia on postoperative morphine requirements in patients undergoing laparoscopic cholecystectomy. Read more about this study

Who is it for?
Ages 18 to 64 years
Conditions the study is for
Cholecystectomy, Pain, Postoperative, Opioid Use
What is being tested?
nefopam, ketoprofen, paracetamol and saline infusion, ketoprofen, paracetamol
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
90 participants
Where
1 siteLebanon
Study dates
8 Apr 2021to 19 Oct 2022
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 64 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • ASA physical status I-II
  • Age between 18 and 64 years
  • Patients able to give consent

Who cannot join

  • ASA physical status III to V
  • History of chronic pain
  • Use of an opioid analgesic within 12 hours prior to surgery
  • Alcohol or drug abuse
  • Chronic opioid intake
  • Morbid obesity
Show all 10Show fewer
  • Psychiatric disorder
  • Pregnancy or breast-feeding
  • Intolerance to NSAIDSs
  • Allergy or contraindication to nefopam (acute angle-closure glaucoma, epilepsy, coronary artery disease, prostate adenoma), to morphine or paracetamol (liver failure), to ketoprofen (increased risk of bleeding, stomach or intestinal ulcer, chronic kidney disease) or to dexmedetomidine (uncontrolled hypertension, heart block greater than first degree, or other clinically significant morbidities)

Trial locations and contacts

1 site in 1 country.

Lebanon1 site
  • American University of Beirut Medical center

    Beirut

Other trials in Lebanon

About this study

Official title: The Effect of Intraoperative Nefopam, Ketoprofen and Paracetamol Combination vs Ketoprofen and Paracetamol Combination on Postoperative Morphine Requirements After Laparoscopic Cholecystectomy: A Randomized, Controlled Trial

The goal of this clinical trial is to evaluate the effect of the addition of nefopam to a multimodal analgesic regimen consisting of ketoprofen and paracetamol during sevoflurane- dexmedetomidine-based anesthesia on postoperative morphine requirements in patients undergoing laparoscopic cholecystectomy.

Read the detailed description

Nefopam is a centrally-acting anti-nociceptive compound with supraspinal and spinal sites of action. It inhibits monoamine reuptake, modulates descending serotoninergic pain, and may also interact with a dopaminergic pathway. Because its mechanism of action is distinct from that of other analgesic opioids, nefopam may well have a role in analgesic protocols. The role of nefopam in multimodal analgesia has been extensively investigated in laparoscopic cholecystectomy. However, there is general agreement that more studies are needed to determine the ideal multimodal strategy. No previous study has investigated a combination regimen of the three most commonly prescribed non-opioid analgesics (NOA) (nefopam, ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic cholecystectomy.

The aim of our study is to compare a combination regimen of three NOA (nefopam, ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic cholecystectomy. We will try to demonstrate the benefit with the addition of a third NOA, which is the nefopam, to the double-drug regimen including ketoprofen and paracetamol. Our hypothesis is that this combination regimen of three NOA is associated with less postoperative pain, less opioid consumption, shorter length of post-anesthesia care unit (PACU) stay, and fewer opioid-related adverse effects and postoperative complications compared to the double-drug regimen of ketoprofen and paracetamol.

In this prospective randomized double-blind study, 90 patients aged 18 to 64 years, with American Society of Anesthesiologists (ASA) physical status I and II, will be randomly assigned using a computer-generated random number table to one of two treatment groups. Group A will receive sevoflurane-dexmedetomidine based anesthesia with ketoprofen and paracetamol for postoperative pain control, and group B will receive sevoflurane-dexmedetomidine based anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control. The primary outcome measure of this study is total morphine consumption in PACU. Normally distributed data will be summarized as mean ± SD and non-normally distributed data will be summarized as median [interquartile range]. This study would have an impact on our current practice and may help find out the best multimodal analgesic strategy to control postoperative pain after laparoscopic cholecystectomy.

Being tested
nefopam, ketoprofen, paracetamol, saline infusion, ketoprofen, paracetamol
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • nefopam, ketoprofen, paracetamolDrug

    Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery

  • saline infusion, ketoprofen, paracetamolDrug

    Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery

Study groups in NCT04622813
Study groupRoleWhat they receive
Placebo groupPlacebo comparatorPatients received sevoflurane-dexmedetomidine-based anesthesia with saline, ketoprofen and paracetamol for postoperative pain control,
Receives: Drug: saline infusion, ketoprofen, paracetamol
Multimodal groupExperimentalpatients received sevoflurane-dexmedetomidine-based anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control.
Receives: Drug: nefopam, ketoprofen, paracetamol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total morphine consumption in the post anesthesia care unit

    Total morphine doses consumed after the surgery during the post anesthesia care unit stay of the patient

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

Secondary outcomes (24)
  1. Total fentanyl

    Total fentanyl given intraoperatively.

    Measured: Intraoperatively

  2. Total morphine

    Total morphine on the floor

    Measured: Throughout the patient's stay on the floor

  3. Ketoprofen consumption

    Ketoprofen consumption on the floor

    Measured: Throughout the patient's stay on the floor

  4. Paracetamol consumption

    Paracetamol consumption on the floor

    Measured: Throughout the patient's stay on the floor

  5. Total morphine consumption at 24 hours after surgery

    Total morphine doses consumed at 24 hours after surgery

    Measured: 24 hours after surgery

  6. Number of patients receiving morphine in PACU

    Number of patients receiving morphine in post anesthesia care unit

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  7. Number of patients receiving morphine on the floor

    Number of patients receiving morphine on the floor

    Measured: Throughout the patient's stay on the floor

  8. Number of patients receiving morphine during the first 24 hours after surgery

    Number of patients receiving morphine during the first 24 hours after surgery

    Measured: During the first 24 hours after surgery

  9. Number of patients receiving ketoprofen on the floor

    Number of patients receiving ketoprofen on the floor

    Measured: On the floor

  10. Number of patients receiving paracetamol on the floor

    Number of patients receiving paracetamol on the floor

    Measured: On the floor

  11. NRS pain scores at rest in PACU

    NRS pain scores at rest in post anesthesia care unit

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  12. NRS pain scores at 24 h after surgery

    NRS pain scores at 24 hours after surgery

    Measured: 24 hours after surgery

  13. sedation scores in PACU

    sedation scores in post anesthesia care unit

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  14. Time to first morphine requirement

    Time to first morphine requirement

    Measured: From the time of arrival to PACU until discharge

  15. Time to discharge (readiness) from PACU

    Time to discharge (readiness) from post anesthesia care unit

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  16. Nausea and vomiting

    Incidence and severity of nausea and vomiting

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  17. Rescue antiemetics

    Need for rescue antiemetics

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  18. Pruritus

    Incidence of pruritus

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  19. Respiratory depression

    Incidence of respiratory depression

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  20. Urinary retention

    Incidence of urinary retention

    Measured: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)

  21. Tachycardia

    Episodes of tachycardia

    Measured: Intraoperatively and in PACU

  22. Sweating

    Episodes of sweating

    Measured: Intraoperatively and in PACU

  23. Quality of recovery

    Quality of recovery at 24 h using the QoR-40

    Measured: At 24 hours after the surgery

  24. Overall satisfaction score

    Overall satisfaction score collected one month after surgery.

    Measured: One month after surgery.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2020
  2. Study start8 Apr 2021
  3. Primary completion19 Oct 2022
  4. Study completion19 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04622813
Sponsor's protocol ID
BIO-2020-0375
Status last verified
May 2023
First submitted
30 Oct 2020
Last updated
6 May 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing nefopam, ketoprofen, paracetamol and saline infusion, ketoprofen, paracetamol in people with Cholecystectomy and Pain, Postoperative, run by American University of Beirut Medical Center at 1 site in Lebanon.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total morphine consumption in the post anesthesia care unit (time frame: Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in